Loading
A phase 3 trial of Ivonescimab, Carboplatin, Tislelizumab in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, active and no longer recruiting.
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05840016 by Akeso, with 532 participants enrolled, started 2023-08-17 and due to reach its primary completion in 2025-02-28. Interventions recorded: AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel. Conditions listed: Advanced Squamous Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
A second publication from the trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
This is the paper Europe PMC returns for registry id NCT05840016 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares Akeso, Ivonescimab, Carboplatin, Small-cell lung cancer.
Shares Akeso, Ivonescimab, Carboplatin, Small-cell lung cancer.
Shares Akeso, Ivonescimab, Carboplatin, Small-cell lung cancer.
Shares Akeso, Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Akeso, Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Akeso, Ivonescimab, Carboplatin, Small-cell lung cancer.
Shares Akeso, Ivonescimab, Small-cell lung cancer.
Shares Tislelizumab, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.